Iyappan Ramalakshmi Oviya

Dr. Iyappan Ramalakshmi Oviya


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022
Verified
Book Chapter
Closed access
PDF file
KMK. Mukesh
K. Mukesh
SVSrisurya Ippatapu Venkata
Srisurya Ippatapu Venkata
SCSpandana Chereddy
Spandana Chereddy
EAE. Anbazhagan
E. Anbazhagan
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya

2 November 2023
Verified
Book Chapter
Closed access
PDF file
BRB. Siva Jyothi Natha Reddy
B. Siva Jyothi Natha Reddy
SYSarthak Yadav
Sarthak Yadav
RVR. Venkatakrishnan
R. Venkatakrishnan
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya

1 August 2023 in Journal of King Saud University – Science
Verified
Journal Article
Open access
SVSharmila Velusamy
Sharmila Velusamy
SHSyed Abuthakir Mohamed Husain
Syed Abuthakir Mohamed Husain
SASaud Alarifi
Saud Alarifi
VAVijaya Anand Mariadoss Arokia
Vijaya Anand Mariadoss Arokia
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya

30 September 2024
Verified
Book Chapter
Closed access
PDF file
NAN. Archanaa
N. Archanaa
VDV. Vifert Jenuben Daniel
V. Vifert Jenuben Daniel
SDS. Divya
S. Divya
KRKalpana Raja
Kalpana Raja
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya

11 May 2024 in Genes
Verified
Journal Article
Open access
PDF file
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya
DSDivya Sankar
Divya Sankar
SMSharanya Manoharan
Sharanya Manoharan
APArchana Prabahar
Archana Prabahar
KRKalpana Raja
Kalpana Raja
Alzheimer’s disease (AD), a multifactorial neurodegenerative disorder, is prevalent among the elderly population. It is a complex trait with mutations in multiple genes. Although the US Food and Drug Administration (FDA) has approved a few drugs for AD treatment, a definitive cure remains elusive. Research efforts persist in seeking improved treatment options for AD. Here, a hybrid pipeline is proposed to apply text mining to identify comorbid diseases for AD and an omics approach to identify the common genes between AD and five comorbid diseases—dementia, type 2 diabetes, hypertension, Parkinson’s disease, and Down syndrome. We further identified the pathways and drugs for common genes. The rationale behind this approach is rooted in the fact that elderly individuals often receive multiple medications for various comorbid diseases, and an insight into the genes that are common to comorbid diseases may enhance treatment strategies. We identified seven common genes—PSEN1, PSEN2, MAPT, APP, APOE, NOTCH, and HFE—for AD and five comorbid diseases. We investigated the drugs interacting with these common genes using LINCS gene–drug perturbation. Our analysis unveiled several promising candidates, including MG-132 and Masitinib, which exhibit potential efficacy for both AD and its comorbid diseases. The pipeline can be extended to other diseases.

28 September 2023
Verified
Book Chapter
Closed access
PDF file
ISIppatu Venkata Srisurya
Ippatu Venkata Srisurya
BHB. Harish
B. Harish
KMK. Mukesh
K. Mukesh
CJC. Jawahar
C. Jawahar
GDG. Dhyanasai
G. Dhyanasai
IOIyappan Ramalakshmi Oviya
Iyappan Ramalakshmi Oviya